BRIEF-Envoy Technologies Files Prospectus Relates To Registration Of Resale Of Up To 7.8 Million Shares Of Common Stock-March 2024-www.financetom.com

BRIEF-Envoy Technologies Files Prospectus Relates To Registration Of Resale Of Up To 7.8 Million Shares Of Common Stock

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Envoy Technologies Files Prospectus Relates To Registration Of Resale Of Up To 7.8 Million Shares Of Common Stock

May 25, 2025 11:06 PM

May 1 (Reuters) - Envoy Technologies Inc:

* ENVOY TECHNOLOGIES FILES PROSPECTUS RELATES TO

REGISTRATION OF

RESALE OF UP TO 7.8 MILLION SHARES OF COMMON STOCK BY CO'S

STOCKHOLDERS

* ENVOY TECHNOLOGIES INC: UNLIKE AN INITIAL PUBLIC OFFERING,

THE

RESALE BY THE REGISTERED STOCKHOLDERS IS NOT BEING UNDERWRITTEN

BY ANY INVESTMENT BANK

* ENVOY TECHNOLOGIES INC: HAVE APPLIED TO LIST COMMON STOCK

ON THE

NASDAQ CAPITAL MARKET UNDER THE SYMBOL "EVOY."

* ENVOY TECHNOLOGIES : UPON COMPLETING DIRECT LISTING, BLINK

CHARGING CO WILL BE CO'S SINGLE LARGEST STOCKHOLDER OWNING ABOUT

46.0% COMMON STOCK

Source text:

Further company coverage:

Previous page： Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study Next page： Curanex Pharmaceuticals Prices $15 Million Initial Public Offering

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study

Aug 26, 2025

07:54 AM EDT, 08/26/2025 (MT Newswires) -- Marker Therapeutics ( MRKR ) said Tuesday its investigational therapy MT-601 achieved a 66% objective response rate in patients with relapsed non-Hodgkin lymphoma, and 50% showed a complete response. In the phase 1 study, eight out of 12 non-Hodgkin lymphoma patients responded to treatment, including six with complete responses, Marker Therapeutics ( MRKR...

Curanex Pharmaceuticals Prices $15 Million Initial Public Offering

Aug 26, 2025

07:55 AM EDT, 08/26/2025 (MT Newswires) -- Curanex Pharmaceuticals (CURX) said Tuesday it priced its initial public offering of 3.75 million common shares at $4 each, for gross proceeds of $15 million. IPO underwriters have a 45-day overallotment option to acquire up to 562,500 additional shares. The developmental-stage pharmaceutical company said it expects its shares to start trading on the...

Market Chatter: Stellantis Axes First Level 3 Advanced Driver-Assistance Program

Aug 26, 2025

07:55 AM EDT, 08/26/2025 (MT Newswires) -- Stellantis ( STLA ) has axed its first Level 3 advanced driver-assistance program due to high costs, technology issues, and concerns over market viability, Reuters reported Tuesday, citing three sources familiar with the matter. According to Reuters, a Stellantis ( STLA ) spokesperson said the L3 technology that was announced in February has...

MCF Energy Increased Financing To $1.2 Million

Aug 26, 2025

07:55 AM EDT, 08/26/2025 (MT Newswires) -- MCF Energy ( MCFNF ) overnight Monday increased its previously announced non-brokered financing from $500,000 to $1,200,000. A statement noted the Offering will consist of 24 million units at a price of $0.05 per Unit. Each Unit will consist of one common share and one full common share purchase warrant with each warrant...